Results for this period
Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Expansion of medical specialties in the Medical Business, lower advertising rates in Media Services, sluggish growth in the number of paying members for existing ISP services in the Broadband Business, and declining revenue from DX services.
No applicable matters.
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥10,796 million (YoY +18.8%) |
| Operating profit | ¥454 million (YoY -1.6%) |
| Ordinary income | ¥421 million (YoY +20.2%) |
| Profit attributable to owners of the parent | ¥253 million (YoY +39.2%) |
| Net income per share | ¥52.48 |
| Operating Margin | 4.2 |
| Equity ratio | End of the current fiscal period 32.3 / End of previous period 33.7 |
| Total assets | ¥11,055 million |
| Net assets | ¥3,719 million |
| Cash flows from operating activities | ¥373 million |
| Cash flows from investing activities | ¥-813 million |
| Cash flows from financing activities | ¥30 million |
| Cash and cash equivalents at end of period | ¥2,286 million |
| Full-year earnings forecast | Net Sales ¥12,000 million (YoY +11.1%) / Operating profit ¥610 million (YoY +34.3%) / Ordinary income ¥560 million (YoY +32.9%) / Net income ¥350 million (YoY +38.2%) |
| Annual Dividend Forecast | ¥31.5 → ¥32.7（+3.8%） |
| Payout ratio | 60 |
| Segment revenue | Medical Business ¥2,874,314 thousand (YoY +200.1%) / Platform Business ¥3,396,170 thousand (YoY -2.5%) / Broadband business ¥3,613,647 thousand (YoY -2.8%) / SaaS and DX business ¥915,746 thousand (YoY -1.9%) |
| Segment profit | Medical Business ¥-155,884 thousand / Platform Business ¥549,573 thousand (YoY +1.5%) / Broadband business ¥543,507 thousand (YoY -3.3%) / SaaS and DX business ¥-68,956 thousand |
| Depreciation and amortization | ¥280,108 thousand |
| Impairment loss | Not applicable for the current fiscal year |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥12,920 thousand / Extraordinary loss Head office relocation costs ¥68,690 thousand / Business Withdrawal Losses ¥33,150 thousand / Other ¥10,283 thousand |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 1 / Name of excluded company ㈱NAPBIZ |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for institutional investors and analysts) |
| Issued Shares at Period-End | 4,877,690 Shares |
| Treasury Shares at Period-End | 74,000 Shares |
| Factors Behind Changes in Business Performance | Expansion of medical specialties in the Medical Business, lower advertising rates in Media Services, sluggish growth in the number of paying members for existing ISP services in the Broadband Business, and declining revenue from DX services. |
Items this document does not state (4)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The expansion of medical specialties in the Medical Business drove higher revenue, while lower advertising rates in Media Services adversely affected revenue and operating profit. For the fiscal year ending March 2027, the company expects growth in the Medical Business and SaaS/DX Business, profit generation from existing businesses, and improved profitability in both businesses.